immunology-2018-keynote

2 / 12

1 5 t h I n t e r n a t i o n a l C o n f e r e n c e o n
Immunology
Journal of Clinical Immunology and Allergy
ISSN 2471-304X
J u l y 0 5 - 0 7 , 2 0 1 8
V i e n n a , A u s t r i a
Immunology 2018
Page 27
One of the most significant problems of cancer therapy is the damaging activity
of anticancer drugs against normal body cells. All attempts to develop a
therapeutic agent with a selective cytotoxic effect on tumor cells had no much
success because of the high degree of biological identity between healthy and
malignant cells. The celandine is being used in the medicine over more than 3500
years. The first data concerning the therapeutic effect of the juice of celandine in
the patient with malignant melanoma were published in Germany in 1536. From
that time drugs based on biologically active substances of celandine are widely
used to treat cancer and non-cancer disease. It is well known that tumor cell is
more negatively charged as compared to normal cell. We have used this feature of
the tumor cell to give NSC-631570 a property to selectively interact with it, without
endangering healthy cells and tissues. The drug is strongly positively charged. Due
to this it has an ability to be selectively accumulated in tumor tissue and to induce
tumor cell apoptosis only in tumor cells without harmful effect on normal cells.
The potent selective antitumor effect of NSC-631570 was repeatedly proven by
the results of clinical trials. Until now this preparation has been tested on over
100 cancer cell lines and on 12 normal cell lines and the results of the studies
carried out in more than 120 universities and research centers (in particular at
the National Cancer Institute (the USA)) have shown that the NSC-631570 killed
only cancer cells without having damaged the normal cells what confirmed its
selective effect.
Biography
Wassil Nowicky, Director of Nowicky Pharma and President of
the Ukrainian Anti-Cancer Institute (Vienna, Austria). He has fin-
ished his study at the Radiotechnical Faculty of the Technical
University of Lviv (Ukraine) by the end of 1955 with graduation
to Diplomingeniueur in 1960 whose title was nostrificated in
Austria in 1975. He is the author of over 300 scientific articles
dedicated to cancer research. He is a real member of the New
York Academy of Sciences, member of the European Union for
applied immunology and of the American Association for sci-
entific progress, Doctor honoris causa of the Open international
university on complex medicine in Colombo, honorary member
of the Austrian Society of a name od Albert Schweizer. He has
received the award for merits of National guild of pharmasists
of America, the award of Austrian Society of sanitary, hygiene
and public health services and others.
Immunomodulating properties of the
anti-cancer proton preparation on basis
of greater celandine alkaloids NSC-631570
(Ukrain)
Wassil Nowicky
Nowicky Pharma/ Ukrainian Anti-Cancer Institute, Austria
Wassil Nowicky, Insights Allergy Asthma Bronchitis 2018, Volume: 4
DOI: 10.21767/2471-304X-C1-001